NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Jan. 26, 2017--
Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH),
parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global
leader in the development, manufacture and commercialization of
innovative diagnostic imaging agents and products, today announced the
appointment of Julie McHugh as a member of its Board of Directors,
effective January 25, 2017. The Company's Board of Directors now
consists of nine members.
Ms. McHugh, who will serve as a member of the Compensation Committee of
the Board, brings over 30 years of experience in the pharmaceutical,
biotech and medical devices industries. She recently served as Chief
Operating Officer of Endo Health Solutions, Inc., where she was
responsible for the specialty pharmaceutical and generic drug
businesses. Prior to that, Ms. McHugh was CEO of Nora Therapeutics,
Inc., a venture capital backed biotech start-up company focused on
developing novel therapies for the treatment of infertility disorders.
Previously, she served as Company Group Chairman for Johnson & Johnson's
worldwide virology business unit, and prior to that, she was President
of Centocor, Inc., a J&J subsidiary. In this role, Ms. McHugh oversaw
the development and launches of several products, including Remicade®
(infliximab), Prezista® (darunavir) and Intelence® (etravirine). Prior
to joining Centocor, Ms. McHugh led the marketing communications for
gastrointestinal drug Prilosec® (omeprazole) at Astra-Merck Inc.
Ms. McHugh currently serves on the Board of Directors of Aerie
Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., New Xellia Group
A/S and Trevena Pharmaceuticals, Inc. She previously served on the Board
of Directors of the Biotechnology Industry Organization, the New England
Healthcare Institute, the Pennsylvania Biotechnology Association, EPIRUS
Pharmaceuticals, Inc. and ViroPharma Inc. Ms. McHugh received a Master
of Business Administration from St. Joseph's University and a Bachelor
of Science from Pennsylvania State University.
“We welcome Julie to the Board, and I am confident she will be immensely
valuable to our Company and stakeholders,” said Mary Anne Heino,
President and CEO. “In addition to her significant business expertise,
Julie has a strong background in health policy, innovation and advocacy.
We look forward to the industry perspective and strategic acumen Julie
brings to the table.”
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical
Imaging, Inc. (“LMI”), a global leader in the development, manufacture
and commercialization of innovative diagnostic imaging agents and
products. LMI provides a broad portfolio of products, which are
primarily used for the diagnosis of cardiovascular diseases. LMI’s key
products include the echocardiography contrast agent DEFINITY®
Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite®
(Technetium Tc99m Generator), a technetium-based generator that provides
the essential medical isotope used in nuclear medicine procedures; and
Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent
used to evaluate pulmonary function and for imaging the lungs. Lantheus
is headquartered in North Billerica, Massachusetts with offices in
Puerto Rico and Canada. For more information, visit www.lantheus.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170126005540/en/
Source: Lantheus Holdings, Inc.
Lantheus Holdings, Inc.
Meara Murphy, 978-671-8508